Arylacetamide deacetylase (AADAC)

Arylacetamide deacetylase (AADAC) is a microsomal enzyme encoded by the AADAC gene and primarily located in the liver and gastrointestinal tract, with expression also observed in the brain and other tissues. It belongs to the amidase signature enzyme family, sharing sequence and structural homology with lipases and carboxylesterases. AADAC catalyzes the hydrolysis of arylacetamide, ester, and amide bonds in a variety of drugs and xenobiotics, forming metabolites that are more readily excreted by the body. Its activity is central in drug detoxification, prodrug activation, and influences the pharmacokinetics and safety of several clinically important medications. Genetic variation in AADAC contributes to differential drug responses and adverse reactions in human populations. Furthermore, AADAC’s protein-protein interactions link it to cancer and metabolic diseases, making it relevant in both pharmaceutical metabolism studies and clinical pharmacogenetics.

Other names

AADACMicrosomal arylacetamide deacetylaseDACCES5A1

Hydrolysis of prodrugs to active drugs or metabolites Deacetylation of arylacetamide and related compounds Detoxification of xenobiotics through amide/ester hydrolysis